BioSpace News Archive

Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, today announced the Company will release third quarter 2021 financial results before market open on Thursday, November 4, 2021.

SIGA Technologies, Inc., a commercial-stage pharmaceutical company, announced that management will host a webcast and conference call to provide a business update at 4:30 P.M. ET on Thursday, November 4th, 2021.

OPKO Health, Inc. (NASDAQ: OPK) reports business highlights and financial results for the three months ended September 30, 2021.

NasoNeb, Inc., a developer of innovative intranasal drug delivery and nasal care solutions, is proud to welcome Dr. Brian Rotenberg and Dr. Rodney Schlosser to the Company’s newly-formed Medical Advisory Board.

Medivir AB (Nasdaq Stockholm: MVIR) today announces that the nomination committee now has been appointed ahead of the Annual General Meeting in May 2022.

CytoDyn Inc. today convened and then adjourned the 2021 Annual Meeting of Shareholders (the “Annual Meeting”) without transacting any other business. The Annual Meeting was adjourned to be held virtually on Wednesday, November 24, 2021 at 8:00 a.m. Pacific Time.

Northwest Biotherapeutics, a biotechnology company developing DCVax® personalized immune therapies for solid tumor cancers, announced the completion of two key milestones which are required for production of DCVax products at the Company’s manufacturing facility in Sawston, UK, and which have been a major focus since the completion of initial construction last year.

Cancer Treatment Centers of America® (CTCA) Phoenix is the first hospital in the western half of the U.S. and the first hospital in Arizona to utilize GI Genius – a powerful ally in the fight against colorectal cancer that employs artificial intelligence (AI) to help physicians detect polyps.

Oryzon Genomics, S.A. (ISIN Code: ES0167733015, ORY), a clinical-stage biopharmaceutical company leveraging epigenetics to develop therapies in diseases with strong unmet medical need, today reported financial results for the third quarter of 2021 and provided an update on recent developments.

Co-Diagnostics, Inc. (Nasdaq: CODX), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, announced today it will release its third quarter 2021 results on Thursday, November 11, 2021, after the market close.